Home' Australian Pharmacist : Australian Pharmacist November 2015 Contents Australian Pharmacist November 2015 I ©Pharmaceutical Society of Australia Ltd.
1. Frequent heartburn is classified as:
a) Symptoms experienced once a week.
b) Symptoms experienced every few
c) Symptoms experienced more than once
a week but less than 3 times a week.
d) Symptoms experienced more than
2 times a week, but less than daily.
2. An alarm symptom associated with
gastro-oesophageal reflux disease
b) Hoarseness of the throat.
d) Sleep disturbance.
3. When treating GORD:
a) Proton pump inhibitors (PPIs) are
considered appropriate for frequent
heartburn symptoms (2 week trial),
without the requirement for further
b) H2-antagonists are considered first line
for the treatment of frequent heartburn.
c) Antacids can provide effective relief for
up to 12 hours.
d) Alginates provide short-term symptom
relief of 30–45 minutes.
4. You advise Jennie that in the
near future she will be able to
purchase over-the-counter (OTC)
esomeprazole 20 mg to treat her
frequent symptoms of GORD. Once
available, when counselling, you
a) Esomeprazole is best taken after food.
b) A common side effect of esomeprazole
is dry mouth.
c) Take esomeprazole 20 mg once daily
for a 1 week trial only to check if your
d) Esomeprazole is usually well tolerated.
5. In the overall management of GORD:
a) Lifestyle measures can assist with
b) Lifestyle measures may be helpful to
relieve mild or intermittent symptoms.
c) Antacids are effective as long-term
d) H2-antagonists have a slower onset of
action compared with PPIs.
Answer online at www.psa.org.au
CONTINUING PROFESSIONAL DEVELOPMENT
• Gastro-oesophageal reflux disease
(GORD) is a common condition,
affecting approximately 2 million
• Frequent GORD (symptoms two or
more times per week, but not daily),
especially with night-time symptoms,
can have a significant impact on
quality of life (QOL).
• Common symptoms of GORD include
acid regurgitation and heartburn.
• Alarm symptoms associated with GORD
include dysphagia, odynophagia,
suspected bleeding, nocturnal
chocking or unexplained weight loss.
• Over-the-counter (OTC) treatment
options for GORD are antacids,
- antagonists and proton
pump inhibitors (PPIs).
• PPIs are the most potent agents
with a sustained duration of action
up to 24 hours (allowing for once
• There is evidence to show that
esomeprazole is more effective than
• Lifestyle measures may assist
with the management of mild or
1. Kahrilas PJ. Clinical practice. Gastroesophageal reflux
disease. NEJM 2008;359(16):1700–7 .
2. Australian Institute of Health and Welfare. Gastro-
oesophageal reflux disease. In: General practice in Australia,
health priorities and policies 1998 to 2008. Canberra: AIHW;
2009. At: www.aihw.gov.au/WorkArea/DownloadAsset.
3. Eslick GD, Talley NJ. Gastroesophageal reflux disease (GERD):
risk factors and impact of quality of life – a population-
based study. J Clin Gastroenterol 2009;43(2):111–17 .
4. Knox SA, Harrison CM, Britt HC, et al. Estimating prevalence
of common chronic morbidities in Australia. Med J Aust
5. Boeckxstaens G, El-Serag HB, Smout AJ, et al. Symptomatic
reflux disease: the present, the past and the future
(republished). Postgrad Med J 2015;91:46–54.
6. Sansom LN, ed. Australian pharmaceutical formulary and
handbook. 23rd edn. Canberra: Pharmaceutical Society of
7. Shaker R, Castell D, Schoenfeld P, et al. Nighttime heartburn
is an under-appreciated clinical problem that impacts
sleep and daytime function: the results of a Gallup survey
conducted on behalf of the American Gastroenterological
Association. Am J Gastroenterol 2003;98(7):1487–93 .
8. Kulig M, Leodolter A, Vieth M, et al. Quality of life in relation
to symptoms in patients with gastro-oesophageal reflux
disease – an analysis based on the ProGERD initiative.
Aliment Pharmacol Ther 2003;18(8):767–76.
9. Farup C, Kleinman L, Sloan S, et al. The impact of nocturnal
symptoms associated with gastroesophageal reflux
disease on health-related quality of life. Arch Intern Med
10. DeGiorgi F, Palmiero M, Esposito I, et al. Pathophysiology of
gastro-oesophageal reflux disease. Acta Otorhinolaryngol
Ital 2006;26:241–6 .
11. DiMarino MC. Gastroesophageal reflux disease (GERD).
In: Merck Manuals professional version. 2014. At: www.
12. Olbe L, Carlsson E, Lindberg P. A proton-pump inhibitor
expedition: the case histories of omeprazole and
esomeprazole. Nat Rev Drug Discov 2003;2(2):132–9 .
13. DiMarino MC. Overview of acid secretion. In: Merck Manuals
professional version. 2014. At: www.msdmanuals.com/
14. Vakil N, van Zanten SV, Kahrilas P, et al. The Montreal
definition and classification of gastroesophageal reflux
disease: a global evidence-based consensus. Am J
15. Ronkainen J, Agréus L. Epidemiology of reflux
symptoms and GORD. Best Pract Res Clin Gastroenterol
16. Digestive Health Foundation c/- Gastroenterological
Society of Australia. Information about heartburn
(oesophageal reflux). Victoria: DHF; 2010. At: www.gesa.org.
17. Digestive Health Foundation c/- Gastroenterological
Society of Australia. Clinical update: reflux disease –
gastro-oesophageal reflux disease in adults. 5th edn.
Victoria: Gastroenterological Society of Australia; 2011. At:
18. Haag S, Andrews J, Katelaris P, et al. Management of reflux
symptoms with over-the-counter proton pump inhibitors:
issues and proposed guidelines. Digestion 2009;80:226–34.
19. Holtmann G, Bigard MA, Malfertheiner P, et al. Guidance on
the use of over-the-counter proton pump inhibitors for the
treatment of GERD. Int J Clin Pharm 2011;33(3):493–500.
20. Gastrointestinal drugs. In: Rossi S, ed. Australian medicines
handbook. Adelaide: Australian Medicines Handbook; 2015.
21. National Institute of Health and Care Excellence (NICE).
Dyspepsia and gastro-oesophageal reflux disease:
investigation and management of dyspepsia, symptoms
suggestive of gastro-oesophageal reflux disease, or both.
2014. At: www.nice.org.uk/guidance/cg184
22. Mandel KG, Daggy BP, Brodie DA, et al. Review article:
alginate-raft formulations in the treatment of heartburn
and acid reflux. Aliment Pharmacol Ther 2000;14(6):669–90 .
23. Gastroenterology Expert Group. Therapeutic guidelines:
gastroenterology, version 5. Melbourne: Therapeutic
24. Tonini M, Vigneri S, Savarino V, Scarpignato C. Clinical
pharmacology and safety profile of esomeprazole, the first
enantiomerically pure proton pump inhibitor. Dig Liver Dis
25. Nexium product information. In: eMIMS cloud. Sydney:
MIMS Australia; 2015.
26. Katz PO, Castell DO, Levine D. Esomeprazole resolves
chronic heartburn in patients without erosive oesophagitis.
Aliment Pharmacol Ther 2003;18(9):875–82.
27. Lind T, Rydberg L, Kylebäck A, et al. Esomeprazole provides
improved acid control vs. omeprazole in patients with
symptoms of gastro-oesophageal reflux disease. Aliment
Pharmacol Ther. 2000;14(7):861–7 .
28. NPS MedicineWise. Health professional information on
heartburn and reflux. Non-pharmacological management
of gastro-oesophageal reflux disease (GORD). 2015. At:
Links Archive Australian Pharmacist October 2015 Australian Pharmacist December 2015 Navigation Previous Page Next Page